Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
GLP-1 receptor agonists can help facilitate weight loss in eligible patients, but response rates and outcomes depend on multiple individual factors beyond the medication itself. Clinical evidence shows average weight loss ranging from 5-22% of body weight over 68 weeks, depending on the specific agent and patient characteristics.
At PlexusDx, we recognize that medication selection and dosing benefit from understanding your unique metabolic and genetic context. Our precision-wellness approach combines compounded GLP-1 options with optional genetic insights to support more personalized conversations with your provider about which treatment may align best with your health goals.
How GLP-1 Medications Work for Weight Loss
GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which regulates appetite and blood sugar. They slow gastric emptying, increase feelings of fullness, and reduce hunger signals in the brain. These mechanisms support caloric deficit without requiring extreme dietary restriction.
Weight loss typically begins within 2-4 weeks, with progressive results over 3-6 months. Efficacy is enhanced when combined with sustained dietary changes and physical activity. Individual response varies due to genetics, baseline metabolism, adherence patterns, and underlying health conditions.
Key Variables That Shape Your Individual Weight Loss Response
Not everyone responds identically to GLP-1 therapy. Age, baseline BMI, insulin resistance, metabolic rate, medication adherence, diet quality, exercise patterns, and genetic predispositions all influence outcomes. Understanding these factors helps your provider set realistic expectations and adjust dosing or treatment strategy as needed.
| Response Factor |
Clinical Significance |
| Baseline Metabolic Rate |
Higher baseline metabolism may require dose optimization; lower rates respond more predictably to standard dosing. |
| Insulin Resistance Status |
Patients with metabolic syndrome often see improved insulin sensitivity alongside weight loss, enhancing overall metabolic health. |
| GLP1R Gene Variants |
Specific genetic predispositions in the GLP1R pathway may support provider discussion on expected response trajectory and titration strategy. |
| Adherence & Lifestyle |
Consistent medication use combined with dietary adherence yields 2-3x greater weight loss compared to medication alone. |
| Age & Baseline BMI |
Younger patients and those with higher baseline BMI often see greater absolute weight loss; older patients show steadier, sustained outcomes. |
Clinical Evidence on Weight Loss Outcomes
Semaglutide (Ozempic/Wegovy) clinical trials showed 14-22% weight loss over 68 weeks at therapeutic doses. Tirzepatide (Zepbound), a GLP-1/GIP dual agonist, demonstrated 20-22% weight loss in similar timeframes. Oral formulations show slightly lower bioavailability but remain clinically effective when dosed appropriately.
Weight loss plateaus typically occur around 6 months, then stabilize with continued therapy. Discontinuation often results in weight rebound within 6-12 months. Long-term treatment is generally recommended to maintain benefits. Combination with lifestyle modification produces superior sustained outcomes versus medication alone.
Medical Considerations and Provider Assessment
GLP-1 therapy requires baseline evaluation including fasting glucose, A1C, lipid panel, renal function, and personal/family history of pancreatitis or thyroid cancer. Contraindications include type 1 diabetes, severe kidney disease, and personal history of medullary thyroid carcinoma. Pregnancy and nursing are relative contraindications requiring provider discussion.
Common side effects include nausea, vomiting, diarrhea, and constipation—typically mild and transient. More serious but rare events include acute pancreatitis and gallbladder complications. Your provider should monitor for these throughout treatment. Dose adjustments or alternative agents may be considered if adverse effects limit tolerability.
How PlexusDx Supports a More Personalized Approach
PlexusDx offers the Precision Peptide Genetic Test to examine your predispositions in key GLP-1 pathway genes—including GLP1R rs6923761 and GIPR rs1800437—which may help provide context for how your body's GLP-1 signaling machinery is structured. This insight should be interpreted with your qualified healthcare provider to support more informed treatment selection and dosing conversations, not to predict exact medication response.
The Precision Peptide Genetic Test also evaluates predispositions in metabolic pathway genes like FTO rs9939609 and MC4R rs17782313, which relate to baseline appetite regulation and energy expenditure. These genetic markers may help explain your individual baseline metabolism and appetite patterns, potentially informing realistic expectations for weight loss outcomes and treatment strategy adjustments.
Genetic insights work alongside clinical assessment—not as a replacement for it. When combined with your bloodwork, medical history, and lifestyle factors, this information can support a more personalized discussion with your provider about whether a compounded semaglutide, tirzepatide, or our GLP-Squared dual compound aligns with your unique metabolic profile and health goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can GLP-1 medications guarantee weight loss?
No. While GLP-1 medications help facilitate weight loss in appropriate candidates, outcomes depend on individual factors including baseline metabolism, medication adherence, diet, and exercise. Average weight loss ranges from 5-22% of body weight over several months, but individual results vary significantly.
How quickly will I see weight loss results on GLP-1 therapy?
Weight loss typically begins within 2-4 weeks and progresses over 3-6 months. Most patients reach a stable plateau around 6 months, after which weight stabilizes with continued treatment. Results are enhanced when combined with dietary changes and regular physical activity.
What are PlexusDx's compounded GLP-1 options and their costs?
PlexusDx offers compounded semaglutide injection ($149/mo), oral semaglutide ($249/mo), tirzepatide injection ($249/mo), oral tirzepatide ($279/mo), and GLP-Squared dual compound ($249/mo)—all from licensed 503A pharmacies. Microdose GLP-1 Protocol starts at $129/mo for exploring tolerability.
What side effects should I expect, and are they serious?
Common side effects—nausea, vomiting, constipation, diarrhea—are usually mild and temporary. Serious but rare complications include pancreatitis and gallbladder issues. Your provider monitors for these throughout treatment and can adjust dosing or switch agents if adverse effects limit tolerability.
How does the Precision Peptide Genetic Test help with GLP-1 treatment?
The test examines predispositions in GLP1R and GIPR genes, plus metabolic markers like FTO and MC4R, which may provide context for your appetite regulation and GLP-1 pathway structure. These insights should be interpreted with your provider to support more informed dosing and medication selection conversations.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Illness While Taking Semaglutide: What You Need to Know
How Often Can I Inject Ozempic: A Comprehensive Guide